Skip to content
Study details
Enrolling now

Feasibility/Acceptability of Attentional-Control Training in Survivors

Children's National Research Institute
NCT IDNCT05528939ClinicalTrials.gov data as of Apr 2026
Target enrollment

50

Study length

about 2.2 years

Ages

8–16

Locations

1 site in DC

What this study is about

Researchers are testing whether a treatment called EndeavorRx can help children who have finished cancer or brain tumor treatment improve their attention. The trial will involve comparing EndeavorRx to a control video game, and it aims to see if the treatment is feasible and acceptable for these young people.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Control video game
  • 2.Use EndeavorRx

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Change from baseline executive functioning assessed by the Behavior Rating Inventory of Executive Functioning, Second Edition (BRIEF-2) Cognitive Regulation Index (CRI) at end of training, Change from baseline inattention assessed by Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3) at 4-month follow-up (16 weeks post-training/control +/- 4 weeks), Change from baseline inattention assessed by Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3) at end of training, Change from baseline inattention assessed by the ADHD Rating Scale, Fifth Edition (ADHD-RS-5) Inattention subscale at 4-month follow-up (16 weeks post-training/control +/- 4 weeks), Change from baseline inattention assessed by the ADHD Rating Scale, Fifth Edition (ADHD-RS-5) Inattention subscale at end of training, Change from baseline inhibitory control assessed by the Behavior Rating Inventory of Executive Functioning, Second Edition (BRIEF-2) Inhibit subscale at 4-month follow-up (16 weeks post-training/control +/- 4 weeks), Change from baseline inhibitory control assessed by the Behavior Rating Inventory of Executive Functioning, Second Edition (BRIEF-2) Inhibit subscale at end of training

Body systems

Oncology